title: DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis.
abstract: BACKGROUND
  Psoriasis is a skin inflammatory chronic disease with negative physical, psychological and social repercussions for those affected. However, patients suffering from mild disease also complain about negative impact on their quality of life, making it difficult for physicians to choose the best treatment strategy.
  
  
  OBJECTIVE
  Understanding the impact of systemic treatments on Quality of Life (QoL) in patients with mild psoriasis in daily practice.
  
  
  METHODS
  This is a monocentric retrospective study analysing patients affected by mild psoriasis [Psoriasis Area and Severity Index (PASI) ≤ 6]. Patients were divided into two groups, depending on the treatment decision taken by the physicians: patients who received local and/or UV light therapies and patients who were treated with systemic therapies as a first choice. PASI and Dermatology Life Quality Index (DLQI) scores were measured at each visit.
  
  
  RESULTS
  Patients who received systemic therapies as a first choice reported higher QoL impairment, mainly due to psoriasis lesions localized on visible areas. During Follow-up, this group showed better improvement of PASI score and DLQI compared to patients receiving local and/or UV light treatment.
  
  
  CONCLUSIONS
  Our findings highlight the potential benefit of using systemic therapies in patients with mild psoriasis and high QoL impairment. This study will help physicians to make the right therapeutic decision in patients suffering from mild psoriasis.
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin disorders, Hôpital Saint-André, Bordeaux, France.
authors.forename: D
authors.initials: D
authors.lastname: Mermin
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin disorders, Hôpital Saint-André, Bordeaux, France.
authors.forename: L
authors.initials: L
authors.lastname: Boursault
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin disorders, Hôpital Saint-André, Bordeaux, France.
authors.forename: B
authors.initials: B
authors.lastname: Milpied
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin disorders, Hôpital Saint-André, Bordeaux, France.
authors.forename: A
authors.initials: A
authors.lastname: Taieb
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin disorders, Hôpital Saint-André, Bordeaux, France.
authors.forename: K
authors.initials: K
authors.lastname: Ezzedine
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin disorders, Hôpital Saint-André, Bordeaux, France. julien.seneschal@chu-bordeaux.fr.
authors.forename: J
authors.initials: J
authors.lastname: Seneschal
mesh_terms: D000328:Adult; D000368:Aged; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents